COLON ERDERLY LOW DOSE
Recruiting · NCT06840977 · Observational (researchers observe without assigning treatment) · Lead sponsor: Matteo Clavarezza
View the official record on ClinicalTrials.gov →What this trial is about
In this retrospective observational study, the case series of patients undergoing first-line treatment for metastatic colorectal adenocarcinoma with doublet fixed-dose and reduced-dose chemotherapy in combination with full-dose monoclonal antibody in patients aged 70 years or older is collected.
Who can take part
Age range
70 Years to 99 Years
Sex
All (male and female)
Healthy volunteers
No - a diagnosis or condition is required
Phase
Not specified
Study type
Observational (researchers observe without assigning treatment)
Inclusion criteria
- Patients with metastatic colorectal adenocarcinoma not treated with any therapy in the metastatic phase. Previous (neo)-adjuvant treatment with fluoroderivatives with or without Oxaliplatin is permitted.
- Age ≥ 70 years
- G8 score ≥ 12
- Patients with colorectal adenocarcinoma MSS
- Patients with BRAF WT colorectal adenocarcinoma
- Ability to understand and sign the informed consent form.
Exclusion criteria
- Patients with MSI tumours
- Patients with BRAF V600E mutated tumours
- Patients not eligible for doublet chemotherapy by clinical decision
Where it is running
2 locations listed.
- E.O. Ospedali Galliera - Genova, GE, Italy
- E.O. Ospedali Galliera - Genoa, Liguria, Italy